AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1483069
Drug: Inhaled platelet-activating
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled platelet-activating factor (200 micrograms)
Trial: 3912961
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for TENS
Trial: 26015451
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (four times daily at 60% to 70% of VO2max for four weeks)
Trial: 25346155
Drug: OXN PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN PR (combined prolonged-release oxycodone and naloxone)
Trial: 25346155
Drug: Oxy PR
RxNorm normalized name: Acarboxy prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy PR (oxycodone prolonged-release tablets)
Trial: 22169699
Drug: Intra-articular hyaluronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular hyaluronic acid (HA) treatment (3 weekly injections of 2 ml of 20 mg/ml HA)
Trial: 22169699
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) (3 weekly injections of 1.2 ml of 0.001 mg/ml HA)
Trial: 7853086
Drug: Rectal thermometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal thermometer
Trial: 2697210
Drug: methylprednisolone plus
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone plus low‐dose cyclosporin A (CyA; median dose 109 mg/m2 per day = 3.4 mg/kg per day after 1 year)
Trial: 2697210
Drug: methylprednisolone plus
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone plus low‐dose cyclosporin A (CyA)
Trial: 29870029
Drug: Non-metformin (Control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-metformin (Control)
Trial: 22497697
Drug: Etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETR) 200mg twice daily (bid)
Trial: 17846101
Drug: Brief Problem‐Solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Problem‐Solving Therapy in Home Care (PST‐HC)
Trial: 8052342
Drug: Miglitol 200
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol 200 mg at bedtime
Trial: 31340042
Drug: ChAd155-RSV low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ChAd155-RSV low dose (5 × 10^9 viral particles)
Trial: 26407616
Drug: Sub‐fascial continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub‐fascial continuous local anaesthetic wound infusion (CLAWI) with 0.2% Bupivacaine plus intravenous paracetamol and rescue intravenous morphine
Trial: 26407616
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine (EPI) plus paracetamol and rescue intravenous morphine
Trial: 26407616
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine and paracetamol (standard post‐operative analgesia—SAPA)
Trial: 15562267
Drug: Methionine load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine load (100 mg/kg of body weight)
Trial: 11473657
Drug: NESP (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NESP (0.45 microg/kg once weekly)
Trial: 11473657
Drug: rHuEPO (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (50 U/kg twice weekly)
Trial: 2921077
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2,160 mg/day)
Trial: 26684819
Drug: IL-7 injections
RxNorm normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-7 injections (3 weekly injections at weeks 8, 9, and 10)
Trial: 26684819
Drug: IL-7 injections
RxNorm normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-7 injections
Trial: 26684819
Drug: IL-7 injections
RxNorm normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-7 injections and dual ART intensification
Trial: 22940889
Drug: Intravenous iron(III)‐hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron(III)‐hydroxide sucrose complex, three doses of 100 mg/24 h during pre‐ and postoperative hospitalization and 1 pill/24 h of oral placebo
Trial: 22940889
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous fumarate iron 1 pill/24 h pre‐ and postoperatively and during 1 month after discharge, and intravenous placebo while hospitalized
Trial: 22940889
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous placebo pre‐ and postoperatively
Trial: 20208358
Drug: D-psicose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-psicose (5 g)
Trial: 20208358
Drug: D-glucose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-glucose (5 g)
Trial: 18975521
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil 40 mg every 8 hours
Trial: 10397379
Drug: Atovaquone and
RxNorm normalized name: Atovaquone and proguanil only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone and proguanil (1000 mg and 400 mg respectively, administered orally at 24-hour intervals for 3 doses)
Trial: 10397379
Drug: Pyrimethamine/sulfadoxine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine/sulfadoxine (75 mg/1500 mg administered orally as a single dose)
Trial: 6538844
Drug: Cimoxatone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimoxatone, 40 mg oral dose
Trial: 12225492
Drug: Short-term and
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term and long-term treatment
Trial: 29486514
Drug: ACE-083 (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-083 (50-200 mg) administered unilaterally into rectus femoris (RF) or tibialis anterior (TA) muscles as 1 or 2 doses 3 weeks apart
Trial: 20040005
Drug: XIENCE V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XIENCE V everolimus eluting coronary stent system (everolimus doses ranging from 53 to 181 microg)
Trial: 16150687
Drug: Child Dissociative
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Dissociative Checklist (CDC) administered to children with abuse histories
Trial: 16150687
Drug: Child Dissociative
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Dissociative Checklist (CDC) administered to children with ADHD
Trial: 16150687
Drug: Child Dissociative
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Dissociative Checklist (CDC) administered to control group (no abuse or psychiatric record)
Trial: 10027428
Drug: Spiros Inhalation
RxNorm normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiros Inhalation System (Dura Pharmaceuticals; 108 microg/actuation of albuterol sulfate equivalent to 90 microg of albuterol base)
Trial: 10027428
Drug: albuterol metered-dose
RxNorm normalized name: albuterol Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albuterol metered-dose inhaler (MDI; 90 microg/actuation of albuterol)
Trial: 8622105
Drug: Isepamicin 15
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 15 mg/kg once daily (n = 15)
Trial: 8622105
Drug: Isepamicin 8
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 8 mg/kg once daily (n = 93)
Trial: 8622105
Drug: Amikacin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 7.5 mg/kg twice daily (n = 18)
Trial: 8622105
Drug: Amikacin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin 7.5 mg/kg twice daily (n = 47)
Trial: 19307466
Drug: Lisinopril/spironolactone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril/spironolactone (40 mg lisinopril/25 mg spironolactone)
Trial: 17589899
Drug: Body awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body awareness therapy (2 hours weekly for 24 weeks)
Trial: 17589899
Drug: Body awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body awareness therapy
Trial: 11120401
Drug: Psychotherapeutic interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic interventions related to pharmacotherapy treatment adherence
Trial: 11120401
Drug: Pharmacologic measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic measures of medication adherence
Trial: 11120401
Drug: Treatment adherence
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment adherence interventions scale ratings
Trial: 1926651
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol (Monuril), 3-gram single dose
Trial: 1926651
Drug: Norfloxacin (Noroxine),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (Noroxine), 400 mg twice daily for 5 days
Trial: 31956037
Drug: Intensified platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified platinum-based chemotherapy
Trial: 31291055
Drug: Initial mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial mild to moderate daily GER
Trial: 27078989
Drug: Shenyi Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyi Capsule + Modified Yiqi Chutan Recipe (MYCR) + chemotherapy
Trial: 27078989
Drug: Shenyi Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenyi Capsule + MYCR + chemotherapy
Trial: 24262291
Drug: Insulin-stimulation after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-stimulation after high-fat overfeeding
Trial: 22128078
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg subcutaneously every two weeks for 12 months
Trial: 21156950
Drug: Protective ventilatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective ventilatory strategy (tidal volumes of 6‐8 mL/kg, PEEP of 8‐10 cm H(2)O)
Trial: 21156950
Drug: Conventional ventilatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ventilatory strategy (tidal volumes of 10‐12 mL/kg, PEEP of 3‐5 cm H(2)O)
Trial: 16330984
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy for 6 weeks after negative venograms
Trial: 3533272
Drug: Tizanidine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine (maximum daily dose 18 mg)
Trial: 3533272
Drug: Carbamazepine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (maximum daily dose 900 mg)
Trial: 18561584
Drug: Once-daily azelaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily azelaic acid 15% gel
Trial: 18561584
Drug: Twice-daily azelaic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily azelaic acid 15% gel
Trial: 8685201
Drug: Tianeptine 25
RxNorm normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine 25 mg/day
Trial: 8685201
Drug: Mianserin 30
RxNorm normalized name: mianserin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 30 mg/day
Trial: 8685201
Drug: Tianeptine 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine 37.5 mg
Trial: 24686107
Drug: Glucose-insulin-potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (GIK) administered in ambulances
Trial: 16216096
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, group C)
Trial: 12011122
Drug: rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab 375 mg/m2 IV weekly for four doses (n = 70)
Trial: 9892509
Drug: Intravenous prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prostaglandin E1 (15 microg i.v. over 30 min)
Trial: 2551907
Drug: Intravenous polymyxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous polymyxin B during the first week after burn injury
Trial: 61952
Drug: FZ. 560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FZ. 560 (combination of fentonium bromide 10 mg, dehydrocholic acid 25 mg, pancreatin 50 mg, lactulose 200 mg)
Trial: 61952
Drug: Fentonium bromide
RxNorm normalized name: Potassium Bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentonium bromide 10 mg (control group)
Trial: 29084409
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (reference medicine)
Trial: 26416999
Drug: Epirubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin plus cyclophosphamide followed by docetaxel (EC-T; 90 mg/m2 epirubicin, 600 mg/m2 cyclophosphamide, 100 mg/m2 docetaxel)
Trial: 26416999
Drug: Epirubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin plus docetaxel followed by capecitabine (ET-X; 90 mg/m2 epirubicin, 75 mg/m2 docetaxel, 1250 mg/m2 capecitabine)
Trial: 15986587
Drug: Etiology of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiology of CL (e.g., alcoholism)
Trial: 12701670
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and placebo (control group)
Trial: 7019930
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tiaprofenic acid given 3-times daily for 7 days
Trial: 7019930
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg aspirin given 3-times daily for 7 days
Trial: 29040445
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg b.i.d. ticagrelor
Trial: 29040445
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg b.i.d. ticagrelor
Trial: 26395889
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 or 200 mg)
Trial: 8673548
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal treatment (31 Chinese herbs), 28 tablets each day
Trial: 8673548
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose placebo), 28 tablets each day
Trial: 1890532
Drug: 1.25% AmF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25% AmF gel
Trial: 1890532
Drug: 0.4% F
RxNorm normalized name: Zest Overdenture 0.4% Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% F gel
Trial: 1890532
Drug: 0% F
RxNorm normalized name: UREA 30% FOAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% F gel
Trial: 1890532
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups during 6-month discontinuation
Trial: 6311009
Drug: Tobramycin or
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin or other comparative agents
Trial: 29342199
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose metformin (375 mg followed by 250 mg)
Trial: 29342199
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose metformin (1000 mg followed by 1000 mg)
Trial: 29342199
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of metformin
Trial: 26774115
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 (500 μg) and folic acid (400 μg)
Trial: 24815501
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment in the same center
Trial: 21971437
Drug: Intramuscular Tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Tramadol (Group TIM)
Trial: 20646181
Drug: Fluoxetine (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20mg qd)
Trial: 17565489
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg rosiglitazone
Trial: 16485509
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy intervention (not specified in detail)
Trial: 16485509
Drug: Medications (antiparkinsonian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications (antiparkinsonian drugs)
Trial: 7389323
Drug: Topical idoxuridine
RxNorm normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical idoxuridine 0.5% and 5% in petrolatum
Trial: 7389323
Drug: Topical idoxuridine
RxNorm normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical idoxuridine 5‐40% in dimethylsulfoxide (previous treatment)
Trial: 21917635
Drug: Intrinsically l‐[1‐(13)C]phenylalanine‐labeled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrinsically l‐[1‐(13)C]phenylalanine‐labeled casein protein (PRO)
Trial: 19116389
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg of ascorbic acid daily)
Trial: 17324218
Drug: Intracameral mydriatics
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral mydriatics (ICMs) with 0.6 microg/ml epinephrine
Trial: 17324218
Drug: Topical mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mydriatics (TMs) with 0.6 microg/ml epinephrine
Trial: 17324218
Drug: Topical mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mydriatics (TMs) without epinephrine
Trial: 14717965
Drug: SanOrg34006 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SanOrg34006 2.5 mg
Trial: 14717965
Drug: SanOrg34006 (5.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SanOrg34006 (5.0, 7.5, 10 mg)
Trial: 14717965
Drug: Warfarin (INR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR, 2.0-3.0)
Trial: 14717965
Drug: SanOrg34006 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SanOrg34006 (all doses)
Trial: 9675647
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxycillin 1000 mg b.i.d. for one week
Trial: 9675647
Drug: Tinidazole 500
RxNorm normalized name: tinidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 500 mg b.i.d. for one week
Trial: 9675647
Drug: Pre-treatment Delta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment Delta Over Baseline at 30' value
Trial: 9675647
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and post-treatment Delta Over Baseline at 30' values
Trial: 25388940
Drug: CT-322 monotherapy
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-322 monotherapy at 1 mg/kg IV weekly
Trial: 25388940
Drug: CT-322 monotherapy
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-322 monotherapy at 2 mg/kg IV weekly
Trial: 23596812
Drug: Fuzhengliqi mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzhengliqi mixture (FLM) 60 mL twice a day
Trial: 23596812
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at acupoints Tianshu (ST 25), Shangjuxu (ST 37), Zusanli (ST 36), Dachangshu (BL 25), and Zhigou (TE 6) twice a day
Trial: 23596812
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with FLM and acupuncture
Trial: 23596812
Drug: Mosapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride (5 mg thrice a day) and Macrogol 4000 (10 g twice a day)
Trial: 19349340
Drug: Community-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based rehabilitation therapy for five months
Trial: 19349340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no additional rehabilitation therapy)
Trial: 16193299
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA)